Microsoft's still a bellwether.
For the first time since it went public, Microsoft saw its revenue fall year-over-year. Tempted to buy? Don't.
Although the coffee chain's stock perked higher on stronger-than-expected results, shares should rise further.
Coca-Cola's second-quarter earnings didn't wow Wall Street. That said, the stock can add pop to your portfolio.
Positive results for the company's experimental lupus drug, Benlysta, sent shares skyrocketing by more than 200% on Monday.
This bank is rolling in dough again. Will some flow shareholders' way?
Here's one possible way to play on the quirks in quarterly reports.
Wary investors may be goaded into taking the plunge.
How hard might Obama's health-care plan hit you?
So, where's the recovery?
GE's disappointing second-quarter results suggest that investors should avoid the conglomerate's shares.
Here's a measured options play in case GE brings a few good things to light later this week.